ClinicalTrials.Veeva

Menu
F

Fundacion Respirar | Clinical Independency Research

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

BMS-986278
Tarlatamab
Baricitinib
Bemarituzumab
LY3009104
Gedatolisib
Nivolumab
AP01
Povorcitinib

Parent organization

This site is a part of Fundacion Respirar

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

7 of 8 total trials

A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary Fibrosis

A randomized, double-blind, placebo-controlled clinical study to evaluate the safety and efficacy of 2 doses of inhaled pirfenidone (AP01) versus pla...

Enrolling
Progressive Pulmonary Fibrosis
Drug: AP01
Other: Placebo

The study is being conducted to evaluate the effect of 3 dosing regimens of povorcitinib on pulmonary function

Enrolling
Moderate to Severe Asthma
Drug: ICS-LABA
Other: placebo

The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986278 in participants with Idiopathic Pulmonary Fibrosis.

Enrolling
Idiopathic Pulmonary Fibrosis
Drug: BMS-986278
Drug: BMS-986278 Placebo

The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986278 in Participants with Progressive Pulmonary Fibrosis.

Enrolling
Progressive Pulmonary Fibrosis
Drug: BMS-986278 Placebo
Drug: BMS-986278

The main objective of Part 1 is to evaluate the safety and tolerability of bemarituzumab plus 5-fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6)...

Active, not recruiting
Gastric Cancer
Gastroesophageal Junction Adenocarcinoma
Other: Placebo
Drug: Nivolumab

This is a Phase 3, open-label, randomized, clinical trial evaluating the efficacy and safety of gedatolisib plus fulvestrant and CDK4/6 Inhibitors fo...

Enrolling
Breast Cancer
Drug: Arm A: Gedatolisib + Palbociclib or Ribociclib + Fulvestrant
Drug: Arm B: Palbociclib or Ribociclib + Fulvestrant

The primary objective of this study is to compare the efficacy of tarlatamab with placebo as assessed by progression free survival (PFS).

Enrolling
Small Cell Lung Cancer
Limited Stage Small Cell Lung Cancer
Drug: Placebo
Drug: Tarlatamab

Trial sponsors

Amgen logo
Bristol-Myers Squibb (BMS) logo
A
C
Incyte logo
Lilly logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems